ScholarLens Back to search
2019•Annals of OncologyOpen access

Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND)

Jorge Aparicio, A. Virgili, Jaume Capdevila, Félix Muñoz Boza, Rafael Álvarez, C. Bosch, Juan Carlos Cámara, Carlos Fernández-Martos, Julen Fernández-Plana, Javier Gállego, R. Gallego, Xavier Hernández‐Yagüe, I. Macías Declara, Nuria Rodrı́guez-Salas, Ruth Vera, M. Taberner, Joan Maurel

Open full text 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Panitumumab, FOLFIRI, FOLFOX, Medicine, Irinotecan, Internal medicine, KRAS, Oncology

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND) — Research Paper | ScholarLens